coadministration of weight-based RBV is recommended if testing for Y93H is positive.[12] Additionally, the American Association for the Study of Liver Diseases recommends 12 weeks of SOF/VEL plus RBV, regardless of viral resistance testing, for prior pegIFN/RBV treatment-experienced patients with compensated cirrhosis, in part based on a modest increase in SVR12 rate observed with RBV coadministration in patients with cirrhosis and prior IFN-based treatment experience.[15] The European Association for the Study of the Liver recommends that patients with compensated cirrhosis and/or prior treatment experience who test positive for Y93H in nonstructural protein 5A (NS5A) should also have weight-based RBV coadministered with SOF/VEL.[13] Most recently the American Association for the Study of Liver Diseases recommended 12 weeks of glecaprevir/pibrentasvir for treatment-naive patients with GT3 infection and compensated cirrhosis, without the need for viral resistance testing or RBV coadministration
Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients
Multiple reviewers describe same-day approval followed by delivery within two to three business days, which is among the fastest turnaround times in this review series
Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis
The recovery benefit is measured against an exercise challenge
After eating salmon, the pink feathers of flamingos may turn red due to this carotenoid pigment
